Aptose's Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed AML patients with diverse mutations Safety continues to be a notable hallmark of TUS-based therapies 100% response rate (CR/CRh) at the tw
(Financial Post, 2025-12-06T13:03:27Z)